Olema Pharmaceuticals (OLMA) Free Cash Flow (2020 - 2026)
Olema Pharmaceuticals (OLMA) posted quarterly Free Cash Flow of -$46.0 million for Q1 2026, down 4.57% year-over-year from -$48.2 million in Q1 2025, and down 19.99% quarter-over-quarter from -$38.3 million in Q4 2025.
Olema Pharmaceuticals (OLMA) Free Cash Flow (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported Free Cash Flow for 7 consecutive years, with -$46.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 4.57% year-over-year to -$46.0 million; the TTM figure through Mar 2026 stood at -$148.7 million (down 19.13% YoY), while the FY2025 annual figure was -$146.7 million, down 40.38% from the prior year.
- Free Cash Flow eased to -$46.0 million in Q1 2026 per OLMA's latest filing, from -$38.3 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$17.9 million in Q1 2022 and bottomed at -$46.0 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$27.3 million across 5 years, with a median of -$26.3 million in 2024.
- Annual changes were most pronounced in 2022 — Free Cash Flow slumped 196.56% — and 2023, when it advanced 16.48%.
- Olema Pharmaceuticals' Free Cash Flow stood at -$19.9 million in 2022, then climbed by 7.08% to -$18.5 million in 2023, then tumbled by 42.26% to -$26.3 million in 2024, then slumped by 45.82% to -$38.3 million in 2025, then decreased by 19.99% to -$46.0 million in 2026.
- Business Quant data shows OLMA's Free Cash Flow at -$46.0 million in Q1 2026, -$38.3 million in Q4 2025, and -$34.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Olema Pharmaceuticals | 930.10 Mn | 930.10 Mn | - | -45.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -45.90 Mn |
| Jun 30, 2026 | -45.90 Mn |
| Mar 31, 2026 | -45.99 Mn |
| Mar 31, 2026 | -45.99 Mn |
| Dec 31, 2025 | -38.33 Mn |
| Dec 31, 2025 | -38.33 Mn |
| Sep 30, 2025 | -34.53 Mn |
| Sep 30, 2025 | -34.53 Mn |
| Jun 30, 2025 | -29.88 Mn |
| Jun 30, 2025 | -29.88 Mn |
| Mar 31, 2025 | -43.98 Mn |
| Mar 31, 2025 | -43.98 Mn |
| Dec 31, 2024 | -26.28 Mn |
| Dec 31, 2024 | -26.28 Mn |
| Sep 30, 2024 | -27.02 Mn |
| Sep 30, 2024 | -27.02 Mn |
| Jun 30, 2024 | -27.56 Mn |
| Jun 30, 2024 | -27.56 Mn |
| Mar 31, 2024 | -23.65 Mn |
| Mar 31, 2024 | -23.65 Mn |